• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by IsoPlexis Corporation

    3/21/23 5:20:43 PM ET
    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ISO alert in real time by email
    S-8 POS 1 brhc10050008_s8pos.htm S-8 POS
    As filed with the Securities and Exchange Commission on March 21, 2023

    Registration No. 333-260161
    Registration No. 333-264180

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    POST-EFFECTIVE AMENDMENT NO. 1 TO:
    Form S-8 Registration Statement No. 333-260161
    Form S-8 Registration Statement No. 333-264180

    UNDER
    THE SECURITIES ACT OF 1933

    IsoPlexis Corporation
    (Exact name of registrant as specified in its charter)


    Delaware

    46-2179799
    (State or other jurisdiction of incorporation or organization)

    (IRS Employer Identification No.)

    35 NE Industrial Road
    Branford, Connecticut 06405
    (Address of Principal Executive Offices, Including Zip Code)

    IsoPlexis Corporation 2014 Stock Plan
    IsoPlexis Corporation 2021 Omnibus Incentive Compensation Plan
    IsoPlexis Corporation 2021 Employee Stock Purchase Plan
    (Full title of the plans)

    Scott Chaplin
    Chief Legal Officer
    IsoPlexis Corporation
    35 NE Industrial Road
    Branford, Connecticut 06405
    (203) 208-4111
    (Name, address and telephone number, including area code, of agent for service)

    Please send copies of all communications to:

    Damien R. Zoubek
    Oliver J. Board
    Freshfields Bruckhaus Deringer US LLP
    601 Lexington Avenue, 31st Floor
    New York, New York 10022

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☐
    Accelerated filer
    ☐
           
    Non-accelerated filer
    ☒
    Smaller reporting company
    ☒
           
       
    Emerging growth company
    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE AND DEREGISTRATION OF UNSOLD SECURITIES
     
    These Post-Effective Amendments relate to the deregistration of all shares of common stock, $0.001 par value per share (“Common Stock”), of IsoPlexis Corporation, a Delaware corporation (the “Company” or the “Registrant”), remaining unsold or otherwise unissued under the following Registration Statements on Form S-8 (collectively, the “Registration Statements”) filed by the Company with the Securities and Exchange Commission (the “SEC”):

    File No.
     
    Date Originally Filed
    with the SEC
     
    Name of Equity Plan or Agreement
     
    Shares of
    Common Stock
    333-260161
     
    October 8, 2021
     
    IsoPlexis Corporation 2014 Stock Plan
     
    5,113,324
           
    IsoPlexis Corporation 2021 Omnibus Incentive Compensation Plan
     
    3,271,801
           
    IsoPlexis Corporation 2021 Employee Stock Purchase Plan
     
    389,500
                 
    333-264180
     
    April 7, 2022
     
    IsoPlexis Corporation 2021 Omnibus Incentive Compensation Plan
     
    1,951,800
           
    IsoPlexis Corporation 2021 Employee Stock Purchase Plan
     
    390,360

    On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the “Merger Agreement”), by and among Berkeley Lights, Inc., a Delaware corporation (“Parent”), Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the Company, Merger Sub merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
     
    As a result of the Merger and the related transactions contemplated by the Merger Agreement, the Company has terminated any and all offerings of the Company’s securities pursuant to the Registration Statements. In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance under the Registration Statements that remain unsold at the termination of the offerings, the Company hereby removes from registration all such securities of the Company registered but unsold or otherwise unissued under the Registration Statements, if any, as of the date hereof. The Registration Statements are hereby amended to reflect the deregistration of such securities, and the Company hereby terminates the effectiveness of the Registration Statements.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Branford, State of Connecticut, on March 21, 2023.


    ISOPLEXIS CORPORATION
       

    By:
    /s/ Scott Chaplin


    Name:
    Scott Chaplin


    Title:
    Chief Legal Officer
     
    No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.



    Get the next $ISO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISO

    DatePrice TargetRatingAnalyst
    2/15/2022$17.00 → $12.00Overweight
    Morgan Stanley
    1/27/2022$20.00 → $15.00Outperform
    SVB Leerink
    11/19/2021$24.00Outperform
    Evercore ISI Group
    11/11/2021$17.00 → $20.00Outperform
    SVB Leerink
    11/2/2021$17.00Outperform
    SVB Leerink
    11/2/2021Outperform
    Cowen & Co.
    11/2/2021$16.00Overweight
    Morgan Stanley
    More analyst ratings

    $ISO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley reiterated coverage on IsoPlexis with a new price target

      Morgan Stanley reiterated coverage of IsoPlexis with a rating of Overweight and set a new price target of $12.00 from $17.00 previously

      2/15/22 10:15:01 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SVB Leerink reiterated coverage on IsoPlexis with a new price target

      SVB Leerink reiterated coverage of IsoPlexis with a rating of Outperform and set a new price target of $15.00 from $20.00 previously

      1/27/22 4:33:30 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Evercore ISI Group initiated coverage on IsoPlexis with a new price target

      Evercore ISI Group initiated coverage of IsoPlexis with a rating of Outperform and set a new price target of $24.00

      11/19/21 7:09:33 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    SEC Filings

    See more
    • SEC Form 15-12G filed by IsoPlexis Corporation

      15-12G - IsoPlexis Corp (0001615055) (Filer)

      3/31/23 8:32:18 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IsoPlexis Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits

      8-K - IsoPlexis Corp (0001615055) (Filer)

      3/22/23 8:13:01 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by IsoPlexis Corporation

      S-8 POS - IsoPlexis Corp (0001615055) (Filer)

      3/21/23 5:20:43 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Financials

    Live finance-specific insights

    See more
    • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

      Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

      12/21/22 4:49:03 PM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

      Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP

      12/21/22 4:15:00 PM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022

      BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexis IsoPlexis is empowering labs to leverage the ce

      10/19/22 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by IsoPlexis Corporation (Amendment)

      SC 13D/A - IsoPlexis Corp (0001615055) (Subject)

      6/15/23 4:15:39 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IsoPlexis Corporation (Amendment)

      SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

      2/14/23 4:33:58 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IsoPlexis Corporation (Amendment)

      SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

      2/14/23 2:40:05 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

      PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

      3/21/23 8:02:00 AM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • IsoPlexis Reports Preliminary Full Year 2022 Revenue

      BRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is expected to be in the range of $16.6 to $16.8 million, representing a decrease of approximately 3% to 4% compared to $17.3 million for the full year ended December 31, 2021. Fourth quarter results were lower than expected primarily due to the timing of customer orders for instruments and lower consumable sales, as the previously described macroeconomic head

      1/12/23 4:05:00 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

      Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

      12/21/22 4:49:03 PM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $ISO
    Leadership Updates

    Live Leadership Updates

    See more
    • IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics Companies

      BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Manny Resendes as Global Controller. These three new appointments further strengthen Isoplexis' financial and legal teams. "We are excited to have Mr. Rew, Mr. Khakhar, and Mr. Resendes join our team at IsoPlexis," said Sean Mackay, CEO of IsoPlexis. "These recent hires will strengthen our ability to accelerate our growth trajectory a

      11/30/21 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

      BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

      11/12/21 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

      BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

      11/12/21 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Khakhar Rajesh T.

      4 - IsoPlexis Corp (0001615055) (Issuer)

      3/21/23 5:04:56 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Myers Jason W.

      4 - IsoPlexis Corp (0001615055) (Issuer)

      3/21/23 4:53:55 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Ho Gregory P.

      4 - IsoPlexis Corp (0001615055) (Issuer)

      3/21/23 4:52:06 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care